查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1888684

藥物安全檢測和藥物安全軟體市場規模、佔有率和趨勢分析報告：按功能、部署、最終用途、地區和細分市場預測（2025-2033 年）

Pharmacovigilance And Drug Safety Software Market Size, Share & Trends Analysis Report By Functionality, By Deployment, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10個工作天內

價格

藥物安全檢測與藥物安全軟體市場摘要

2024 年全球藥物安全檢測與藥物安全軟體市場規模為 2.1096 億美元，預計到 2033 年將達到 3.8874 億美元。

預計從 2025 年到 2033 年，該市場將以 7.1% 的複合年成長率成長。數據可用性的提高、處理產生的數據並從中得出見解的需求、嚴格的報告規範和標準，以及主要企業不斷增加的軟體升級，都是推動該市場發展的主要因素。

Accenture的INTIENT藥物警戒平台是一套用於收集和管理藥物警戒資料的綜合產品套件。該平台能夠幫助機構識別潛在的合規性問題、新興趨勢並報告不利事件。藥物不良反應（ADR）和用藥錯誤的發生率不斷上升是推動產業成長的關鍵因素。隨著藥物治療複雜性的增加和多重用藥的普遍存在，醫療保健系統面臨不利事件的風險，這些事件會危及病患安全並增加住院率。 Springer Nature發表的一項研究發現，在2018年6月至2021年5月期間，5707名因急性疾病入院的連續患者中，因藥物不良反應導致的急診住院率為5.0%（95% CI 4.5-5.6%）。這些發現凸顯了開發先進的藥物安全檢測方案的必要性，這些解決方案能夠透過即時監測和自動化報告系統，有效地檢測、分析和預防藥物相關風險。

此外，來自歐洲藥品管理局 (EMA) 和美國食品藥物管理局(FDA) 等政府機構制定的安全準則所帶來的日益成長的合規壓力，也促使藥物安全檢測得到廣泛應用。許多製藥公司正轉向將藥物安全檢測活動外包，以控制營運成本。製造商正逐步從完全一體化的製藥公司模式轉向與服務供應商建立成本分攤的合作夥伴關係。外包服務涵蓋醫學寫作、臨床試驗數據收集、醫學報告以及其他藥物警戒服務。外包能夠提高內部資源的柔軟性，縮短時間，並帶來更好的結果。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場趨勢展望
  • 市場動態
  • 商業環境分析
    • 波特五力分析
    • PESTLE分析

第4章藥物安全檢測和藥物安全軟體市場：按部署方式分類的估算和趨勢分析

  • 部署儀表板
  • 按部署方式分類的市佔率變化分析（2024 年和 2033 年）
  • 按部署方式分類的市場規模、預測與趨勢分析（2021 年至 2033 年）
  • 本地部署
  • 一經請求

第5章藥物安全檢測與藥物安全軟體市場：功能、性別比例估算與趨勢分析

  • 功能性性別儀表板
  • 按功能分類的市佔率變化分析（2024 年和 2033 年）
  • 功能性別市場規模、預測與趨勢分析（2021-2033）
  • 病例資料收集與管理
  • 不利事件通報與分析
  • 訊號偵測及其他安全風險評估

第6章藥物安全檢測和藥物安全軟體市場：按最終用途分類的估算和趨勢分析

  • 按最終用途分類的市佔率變化分析（2024 年和 2033 年）
  • 按最終用途分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫療保健公司（製藥和生物技術公司）
  • CRO/BPO 或 PV服務供應商（外包時）
  • 其他

第7章藥物安全檢測和藥物安全軟體市場：按地區分類的估算和趨勢分析

  • 區域市場概覽
  • 區域市場：主要結論
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 企業市場分析/企業市場占有率分析（2024）
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Oracle（Cerner）
    • Accenture
    • IBM Corporation
    • ITClinical
    • UBC（United BioSource Corporation）
    • Ab Cube
    • Ennov
    • EXTEDO
    • Veeva Systems
    • IQVIA
    • Sarjen Systems Pvt. Ltd.
    • Flex Databases
    • Tepsivo Oy
    • ArisGlobal
    • EVERSANA
Product Code: GVR-1-68038-144-3

Pharmacovigilance And Drug Safety Software Market Summary

The global pharmacovigilance and drug safety software market size was valued at USD 210.96 million in 2024 and is projected to reach USD 388.74 million by 2033, growing at a CAGR of 7.1% from 2025 to 2033. The growing availability of data, the need to process & derive insights from the generated data, stringent reporting norms & standards, and increasing software upgrades by key companies are some of the key drivers of this market.

INTIENT Pharmacovigilance by Accenture is a comprehensive product suite that helps in the collection and management of a full spectrum of pharmacovigilance data. The platform also enables users to understand potential compliance issues and emerging trends and report on adverse events. The rising incidence of adverse drug reactions (ADRs) and medication errors is a key factor driving the growth of the industry. As drug therapies become more complex and polypharmacy increases, healthcare systems face greater risks of adverse events that compromise patient safety and increase hospitalizations. According to an article published by Springer Nature, the proportion of urgent hospitalizations caused by ADRs was reported as 5.0% (95% CI 4.5-5.6%) among 5,707 consecutive patients hospitalized for acute medical illnesses between June 2018 and May 2021. Such findings highlight the critical need for advanced pharmacovigilance solutions that can efficiently detect, analyze, and prevent drug-related risks through real-time monitoring and automated reporting systems.

Moreover, increasing pressure to follow safety guidelines set by government authorities such as the European Medicines Agency and the U.S. FDA is contributing to the growing adoption of pharmacovigilance systems. Many pharmaceutical companies are moving toward outsourcing pharmacovigilance activities to curb operational costs. Manufacturers are gradually shifting from being fully integrated pharmaceutical companies to sharing costs by collaborating with service providers. Services outsourced range from medical writing and clinical trial data collection to medical reporting and other PV services. Outsourcing helps increase internal resource flexibility, improves timelines, and results in better outcomes.

Gobal Pharmacovigilance And Drug Safety Software Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmacovigilance and drug safety software market report based on deployment, functionality, end use, and regions.

  • Deployment Outlook (Revenue, USD Million, 2021 - 2033)
  • On Premise
  • On Demand
  • Functionality Outlook (Revenue, USD Million, 2021 - 2033)
  • Case data collection and management
  • Adverse event reporting and analysis
  • Signal detection and other safety risk assessment
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Healthcare Companies (Pharmaceuticals & Biotechnology Companies)
  • CROs/BPOs or PV service providers when outsourced.
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Deployment
    • 1.2.2. Functionality
    • 1.2.3. End use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing drug consumption and drug development rates
      • 3.2.1.2. Increasing incidence of ADR and drug toxicity
      • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
      • 3.2.1.4. Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 3.2.1.5. Increasing regulatory burden on manufacturers
      • 3.2.1.6. Introduction of technologically advanced software services
      • 3.2.1.7. Rising investment on R&D by healthcare companies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Shortage of skilled professionals
      • 3.2.2.2. Expensive technology for small and mid-sized Players
      • 3.2.2.3. Lack of Recognition
      • 3.2.2.4. Scarcity of integration standards
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. PV Services Pricing Models
      • 3.2.5.1. Drug Safety Budget Allocation By Activities
      • 3.2.5.2. By Development Phase
      • 3.2.5.3. By Therapeutic Area
      • 3.2.5.4. Pricing Level
        • 3.2.5.4.1.Project management
        • 3.2.5.4.2.Case processing
        • 3.2.5.4.3.ADR Reporting
        • 3.2.5.4.4.Medical writing
        • 3.2.5.4.5.Drug safety management
    • 3.2.6. Technology Overview
    • 3.2.7. Case Studies
    • 3.2.8. Inflation's Impact on the Overall PV and Drug Safety Software Market
    • 3.2.9. Market Competitive Factors and Strategies
    • 3.2.10. Healthcare Companies Using PV Services
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal Landscape

Chapter 4. Pharmacovigilance and Drug Safety Software Market: Deployment Estimates & Trend Analysis

  • 4.1. Deployment Dashboard
  • 4.2. Deployment Market Share Movement Analysis, 2024 & 2033
  • 4.3. Market Size & Forecasts and Trend Analysis, by Deployment, 2021 to 2033 (USD Million)
  • 4.4. On-Premise
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. On-Demand
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharmacovigilance and Drug Safety Software Market: Functionality Estimates & Trend Analysis

  • 5.1. Functionality Dashboard
  • 5.2. Functionality Market Share Movement Analysis, 2024 & 2033
  • 5.3. Market Size & Forecasts and Trend Analysis, by Functionality, 2021 to 2033 (USD Million)
  • 5.4. Case data collection and management
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Adverse event reporting and analysis
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Signal detection and other safety risk assessment
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pharmacovigilance and Drug Safety Software Market: End Use Estimates & Trend Analysis

  • 6.1. End use Segment Dashboard
  • 6.2. End use Market Share Movement Analysis, 2024 & 2033
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Healthcare Companies (Pharmaceuticals & Biotechnology Companies)
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. CROs/BPOs or PV service providers when outsourced.
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pharmacovigilance and Drug Safety Software Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market: Key Takeaways
  • 7.3. North America
    • 7.3.1. North America Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamic
      • 7.3.2.2. Regulatory framework
      • 7.3.2.3. Competitive insights
      • 7.3.2.4. U.S. Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamic
      • 7.3.3.2. Regulatory framework
      • 7.3.3.3. Competitive insights
      • 7.3.3.4. Canada Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamic
      • 7.3.4.2. Regulatory framework
      • 7.3.4.3. Competitive insights
      • 7.3.4.4. Mexico Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamic
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive insights
      • 7.4.2.4. Germany Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. UK
      • 7.4.3.1. Key country dynamic
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Competitive insights
      • 7.4.3.4. UK Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamic
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Competitive insights
      • 7.4.4.4. France Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamic
      • 7.4.5.2. Regulatory framework
      • 7.4.5.3. Competitive insights
      • 7.4.5.4. Italy Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamic
      • 7.4.6.2. Regulatory framework
      • 7.4.6.3. Competitive insights
      • 7.4.6.4. Spain Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamic
      • 7.4.7.2. Regulatory framework
      • 7.4.7.3. Competitive insights
      • 7.4.7.4. Denmark Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamic
      • 7.4.8.2. Regulatory framework
      • 7.4.8.3. Competitive insights
      • 7.4.8.4. Sweden Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamic
      • 7.4.9.2. Regulatory framework
      • 7.4.9.3. Competitive insights
      • 7.4.9.4. Norway Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamic
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive insights
      • 7.5.2.4. Japan Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamic
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive insights
      • 7.5.3.4. China Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamic
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive insights
      • 7.5.4.4. India Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamic
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive insights
      • 7.5.5.4. South Korea Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key country dynamic
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive insights
      • 7.5.6.4. Australia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamic
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive insights
      • 7.5.7.4. Thailand Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Pharmacovigilance and Drug Safety Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamic
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive insights
      • 7.6.2.4. Brazil Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamic
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive insights
      • 7.6.3.4. Argentina Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamic
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive insights
      • 7.7.2.4. South Africa Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamic
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive insights
      • 7.7.3.4. Saudi Arabia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamic
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive insights
      • 7.7.4.4. UAE Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamic
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive insights
      • 7.7.5.4. Kuwait Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis/Company Market Share Analysis, (2024)
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Oracle (Cerner)
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial performance
      • 8.5.1.3. Product benchmarking
      • 8.5.1.4. Strategic initiatives
    • 8.5.2. Accenture
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial performance
      • 8.5.2.3. Product benchmarking
      • 8.5.2.4. Strategic initiatives
    • 8.5.3. IBM Corporation
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial performance
      • 8.5.3.3. Product benchmarking
      • 8.5.3.4. Strategic initiatives
    • 8.5.4. ITClinical
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial performance
      • 8.5.4.3. Product benchmarking
      • 8.5.4.4. Strategic initiatives
    • 8.5.5. UBC (United BioSource Corporation)
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial performance
      • 8.5.5.3. Product benchmarking
      • 8.5.5.4. Strategic initiatives
    • 8.5.6. Ab Cube
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial performance
      • 8.5.6.3. Product benchmarking
      • 8.5.6.4. Strategic initiatives
    • 8.5.7. Ennov
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. EXTEDO
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Veeva Systems
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. IQVIA
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Sarjen Systems Pvt. Ltd.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Product benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Flex Databases
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Product benchmarking
      • 8.5.12.4. Strategic initiatives
    • 8.5.13. Tepsivo Oy
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial performance
      • 8.5.13.3. Product benchmarking
      • 8.5.13.4. Strategic initiatives
    • 8.5.14. ArisGlobal
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial performance
      • 8.5.14.3. Product benchmarking
      • 8.5.14.4. Strategic initiatives
    • 8.5.15. EVERSANA
      • 8.5.15.1. Overview
      • 8.5.15.2. Financial performance
      • 8.5.15.3. Product benchmarking
      • 8.5.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 List of secondary data sources
  • Table 3 North America Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 5 North America Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 6 North America Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S. Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 8 U.S. Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 9 U.S. Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 10 Canada Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 11 Canada Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 12 Canada Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 13 Mexico Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 14 Mexico Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 15 Mexico Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Europe Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 17 Europe Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 18 Europe Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 19 Europe Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Germany Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 21 Germany Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 22 Germany Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 23 U.K. Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 24 U.K. Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 25 U.K. Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 26 France Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 27 France Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 28 France Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 29 Italy Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 30 Italy Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 31 Italy Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 32 Spain Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 33 Spain Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 34 Spain Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Sweden Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 36 Sweden Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 37 Sweden Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 38 Denmark Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 39 Denmark Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 40 Denmark Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Norway Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 42 Norway Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 43 Norway Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 48 China Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 49 China Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 50 China Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 51 Japan Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 52 Japan Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 53 Japan Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 54 India Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 55 India Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 56 India Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Australia Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 58 Austarila Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 59 Australia Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 60 Thailand Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 61 Thailand Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 62 Thailand Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 63 South Korea Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 64 South Korea Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 65 South Korea Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 66 Latin America Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 67 Latin America Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 68 Latin America Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 69 Latin America Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 70 Brazil Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 71 Brazil Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 72 Brazil Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 73 Argentina Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 74 Argentina Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 75 Argentina Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 76 MEA Pharmacovigilance and Drug Safety Software market, by country, 2021 - 2033 (USD Million)
  • Table 77 MEA Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 78 MEA Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 79 MEA Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 80 South Africa Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 81 South Africa Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 82 South Africa Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 86 UAE Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 87 UAE Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 88 UAE Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Pharmacovigilance and Drug Safety Software market, by deployment, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Pharmacovigilance and Drug Safety Software market, by functionality, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Pharmacovigilance and Drug Safety Software market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Pharmacovigilance and Drug Safety Software market: Market outlook
  • Fig. 5 Pharmacovigilance and Drug Safety Software market: Segment outlook
  • Fig. 6 Pharmacovigilance and Drug Safety Software market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Pharmacovigilance and Drug Safety Software Market Driver Impact
  • Fig. 9 Pharmacovigilance and Drug Safety Software market Restraint impact
  • Fig. 10 Pharmacovigilance and Drug Safety Software market, deployment outlook key takeaways (USD Million)
  • Fig. 11 Pharmacovigilance and Drug Safety Software market: deployment movement analysis, (USD Million)
  • Fig. 12 On-Premise market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 13 On-demand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 Pharmacovigilance and Drug Safety Software market, functionality outlook key takeaways (USD Million)
  • Fig. 15 Pharmacovigilance and Drug Safety Software market functionality movement analysis, (USD Million)
  • Fig. 16 Case data collection and management market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Adverse event reporting and analysis market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Signal detection and other safety risk assessment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Pharmacovigilance and Drug Safety Software market, end use outlook key takeaways (USD Million)
  • Fig. 20 Pharmacovigilance and Drug Safety Software market: end use movement analysis, (USD Million)
  • Fig. 21 Healthcare Companies (Pharmaceuticals & Biotechnology Companies) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 CROs/BPOs or PV service providers when outsourced market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 Pharmacovigilance and Drug Safety Software market: Regional outlook, 2024 & 2033
  • Fig. 26 North America Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 US Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Canada Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Mexico Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Europe Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 UK Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Germany Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 France Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Italy Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Spain Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Denmark Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Sweden Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Norway Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Asia Pacific Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Japan Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 China Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 India Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 South Korea Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Australia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Thailand Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Latin America Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Brazil Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 MEA Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 South Africa Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Saudi Arabia Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 UAE Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Kuwait Pharmacovigilance and Drug Safety Software market estimates and forecasts, 2021 - 2033 (USD Million)